PFE•benzinga•
Pfizer Revises FY22 Adj. EPS Guidance To $6.25-$6.45 To Reflect $0.11 Negative Impact For Accounting Policy Change; Sees Sales $98B-$102B vs $107.94B Est.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga